发布求助
文献互助 智能选刊 最新文献

Journal of cancer immunology最新文献

筛选
英文 中文
Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies 内源性IL-2引起的Tregs负反馈扩张限制了基于IL-2的治疗的活性
Journal of cancer immunology Pub Date : 2023-05-23 DOI: 10.33696/cancerimmunol.5.074
I. Amit, Natalie Levitin, Meital Gadrich, May Ben-Mayor, T. Wyant, Reut Barak, Liron Danielpur, Morya Ifrach, Itzhak Meir, Olga Bluvshtein, Yehezkel Sasson, Sharon Fischman, Guy Nimrod, Michael Zhenin, Yair Fastman, J. Vasselli, Aron Knickerbocker, R. Herbst, Yanay Ofran
{"title":"Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies","authors":"I. Amit, Natalie Levitin, Meital Gadrich, May Ben-Mayor, T. Wyant, Reut Barak, Liron Danielpur, Morya Ifrach, Itzhak Meir, Olga Bluvshtein, Yehezkel Sasson, Sharon Fischman, Guy Nimrod, Michael Zhenin, Yair Fastman, J. Vasselli, Aron Knickerbocker, R. Herbst, Yanay Ofran","doi":"10.33696/cancerimmunol.5.074","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.074","url":null,"abstract":"Stimulating effector T-cells (Teffs) without inducing regulatory T-cells (Tregs) has been the primary goal of IL-2-based therapies for cancer. Recently, modified IL-2 designed for differential T-cell expansion for the treatment of cancer has failed in the clinic. We propose that treatments based on exogenous administrations of modified IL-2 are inherently undermined by a negative feedback loop, caused by IL-2 secreted endogenously from activated effector T-cells. This endogenous IL-2 secretion subsequentially induces Treg expansion and inhibits the immune response that is essential for cancer clearance. Here, we demonstrate that treatments utilizing exogenous modified IL-2 indeed induce Treg expansion. To circumvent this negative feedback, we computationally designed a novel monoclonal humanized antibody (AU-007) that binds human IL-2 with pM affinity at a predefined epitope and completely blocks IL-2 binding to CD25 that is highly expressed on Tregs, without hindering IL-2 binding to CD122/CD132 dimer receptor expressed over effector cells. This epitope-specific, high-affinity antibody controls endogenous IL-2 and prevents it from expanding Tregs while allowing it to expand Teffs. We show that controlling endogenous IL-2 using AU-007 abrogates the negative feedback loop and replaces it with a positive feedback loop that enhances the expansion of NK cells and Teffs, an effect considered favorable for cancer immunotherapy.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43784319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights from Long Noncoding RNAs into Cancer-immunity Cycle Regulation 长链非编码rna在癌症免疫周期调控中的应用
Journal of cancer immunology Pub Date : 2023-05-23 DOI: 10.33696/cancerimmunol.5.073
Yelin Liang, Yuan Zhang, Xirong Tan, Han Qiao, Jun Ma, Yingqin Li, Na Liu
{"title":"Insights from Long Noncoding RNAs into Cancer-immunity Cycle Regulation","authors":"Yelin Liang, Yuan Zhang, Xirong Tan, Han Qiao, Jun Ma, Yingqin Li, Na Liu","doi":"10.33696/cancerimmunol.5.073","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.073","url":null,"abstract":"Accumulating evidence from recent research offers new perspectives on the functions of long non-coding RNAs (lncRNAs) in immunooncology. In addition to modulating the aggressiveness of cancer cells, lncRNAs are essential players in regulating various immune cells and stromal cells, playing a role in reshaping the tumor microenvironment and affecting anti-tumor immunity. The insightful discoveries on the role of lncRNAs in immuno-oncological activities indicate the prognostic value of lncRNA markers. Here, we present an overview of the roles of lncRNAs derived from different cell types in the tumor microenvironment, that is, immune cells, tumor cells, and stromal cells, and summarize their functional characterization and mechanisms in immuno-oncological activities. We also discuss the opportunities and challenges of single-cell-based technologies for analyzing the cellular function of immune-related lncRNAs.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43063689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Liver Navigation in Surgery Planning and the Challenges 肝脏导航在手术计划中的作用和挑战
Journal of cancer immunology Pub Date : 2023-01-26 DOI: 10.33696/cancerimmunol.5.070
S. Dakua, Sagnika Dash, Sagarika Pati, J. Abinahed
{"title":"Role of Liver Navigation in Surgery Planning and the Challenges","authors":"S. Dakua, Sagnika Dash, Sagarika Pati, J. Abinahed","doi":"10.33696/cancerimmunol.5.070","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.070","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43576908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Integration of Palliative Care for Patients Receiving Systemic Immunotherapy for Renal Cell Carcinoma. 为接受全身免疫疗法的肾细胞癌患者及早纳入姑息治疗。
Journal of cancer immunology Pub Date : 2023-01-01 DOI: 10.33696/cancerimmunol.5.072
Megan Stout, Akshay Thaper, Vivien Xu, Eric A Singer, Biren Saraiya
{"title":"Early Integration of Palliative Care for Patients Receiving Systemic Immunotherapy for Renal Cell Carcinoma.","authors":"Megan Stout, Akshay Thaper, Vivien Xu, Eric A Singer, Biren Saraiya","doi":"10.33696/cancerimmunol.5.072","DOIUrl":"10.33696/cancerimmunol.5.072","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"5 1","pages":"5-12"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9672570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Iodine Misconceptions: A Novel Formulation Approach to Topical Iodine 分子碘的误解:局部碘的新配方方法
Journal of cancer immunology Pub Date : 2022-12-22 DOI: 10.33696/cancerimmunol.4.067
{"title":"Molecular Iodine Misconceptions: A Novel Formulation Approach to Topical Iodine","authors":"","doi":"10.33696/cancerimmunol.4.067","DOIUrl":"https://doi.org/10.33696/cancerimmunol.4.067","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47949465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Surprising Benefit of Cysteine Capping for Antibody Drug Conjugates 半胱氨酸封端用于抗体-药物偶联物的惊人益处
Journal of cancer immunology Pub Date : 2022-12-22 DOI: 10.33696/cancerimmunol.4.068
Xiaotian Zhong, A. D'Antona, K. Dutta
{"title":"A Surprising Benefit of Cysteine Capping for Antibody Drug Conjugates","authors":"Xiaotian Zhong, A. D'Antona, K. Dutta","doi":"10.33696/cancerimmunol.4.068","DOIUrl":"https://doi.org/10.33696/cancerimmunol.4.068","url":null,"abstract":"antibody-Abstract Antibody-drug conjugates (ADCs), combining the best features of monoclonal antibodies and small molecule drugs","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49115903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Higher Frequency and Poor Prognosis with COVID-19 Associated Cytokine Storm among Cancer Patients: Between Two Fires 癌症患者中新冠肺炎相关细胞因子风暴的高频率和低预后：两次火灾之间
Journal of cancer immunology Pub Date : 2022-12-22 DOI: 10.33696/cancerimmunol.4.063
{"title":"Higher Frequency and Poor Prognosis with COVID-19 Associated Cytokine Storm among Cancer Patients: Between Two Fires","authors":"","doi":"10.33696/cancerimmunol.4.063","DOIUrl":"https://doi.org/10.33696/cancerimmunol.4.063","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48929332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer? Butein能成为治疗晚期转移性甲状腺癌的候选药物吗?
Journal of cancer immunology Pub Date : 2022-12-22 DOI: 10.33696/cancerimmunol.4.064
Devavrat Tripathi, S. Kulkarni
{"title":"Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer?","authors":"Devavrat Tripathi, S. Kulkarni","doi":"10.33696/cancerimmunol.4.064","DOIUrl":"https://doi.org/10.33696/cancerimmunol.4.064","url":null,"abstract":"The incidence and prevalence of papillary thyroid cancer (PTC) are increasing worldwide and it is the 5th most common endocrine cancer in females [1]. In addition to this, the frequency of resistance toward radio-iodine therapy is also increasing in PTC patients (Advanced metastatic thyroid cancer). External beam radiation therapy (EBRT) and chemotherapy are used for the treatment of such patients. EBRT and Chemotherapy are associated with serious side effects and toxicity. US-FDA has also approved two drugs (Sorafenib and Lenvatinib) for the treatment of advanced thyroid cancer patients. However, the efficacy of both drugs is limited in terms of overall survival and disease-free survival and associated with severe toxicities [2]. Hence, the treatment of patients with advanced metastatic thyroid cancer represents a major challenge for clinicians and oncologists. In such patients, tumor cells show invasion in local neck regions, lungs, and bones [3]. Metastasis is the most dangerous aspect of cancer and is responsible for 90% of deaths of cancer. Epithelial -mesenchymal transition (EMT) and cancer stem cells (CSC) are the driving forces of metastasis and therapeutic resistance [4]. Hence, this axis of EMT and CSCs is a major target from the new therapy point of view.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45853678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of the Tyrer-Cuzick 8 Breast Cancer Risk Model Across Races: A Review Tyrer-Cuzick 8乳腺癌风险模型跨种族的表现综述
Journal of cancer immunology Pub Date : 2022-12-22 DOI: 10.33696/cancerimmunol.4.065
{"title":"Performance of the Tyrer-Cuzick 8 Breast Cancer Risk Model Across Races: A Review","authors":"","doi":"10.33696/cancerimmunol.4.065","DOIUrl":"https://doi.org/10.33696/cancerimmunol.4.065","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42559873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy 离合器控制:改变CAR-T细胞治疗的速度和方向
Journal of cancer immunology Pub Date : 2022-11-30 DOI: 10.33696/cancerimmunol.4.066
Alberto Nobili, A. Kobayashi, Patrick C. Gedeon, C. Novina
{"title":"Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy","authors":"Alberto Nobili, A. Kobayashi, Patrick C. Gedeon, C. Novina","doi":"10.33696/cancerimmunol.4.066","DOIUrl":"https://doi.org/10.33696/cancerimmunol.4.066","url":null,"abstract":"The adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T cells) has revolutionized the treatment of hematological malignancies, providing unmatched clinical responses in adults and children with relapsed or refractory B cell malignancies. To date, this has","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"4 1","pages":"52 - 59"},"PeriodicalIF":0.0,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46891108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书